GFP fluorescent images of PSMA CAR-T and UTD T cells treated PC3-PSMA+GFP+ tumor spheroids. (Left) PSMA CAR-T cells specifically targeted and induced cytotoxicity in PC3-PSMA+GFP+ spheroids. (Right) UTD T cells did not induce cytotoxicity for all conditions and time points. The 鈥淣o Treatment鈥� images in the panel are the same sample.
News — Oak Brook, IL – The April 2023 issue of SLAS Discovery contains six full-length articles and one mini-review covering high-throughput screening (HTS) for protease-inhibiting drugs, high-content phenotypic screening and other life sciences research.
Featured in this month’s issue is the article “,” by Zurowski, et al, where the authors focus on the use of chimeric antigen receptor T (CAR-T) cells targeting prostate-specific membrane antigen (PSMA), an antigen found in prostate cancer tumor cells. CAR-T cell therapy has proven to be a reliable treatment option for various hematological malignancies, and the discovery of an assay for testing this therapy to solid tumors could yield new possibilities in treating the tumor type present in 90% of all adult human cancers.
The researchers developed a high-throughput assay to analyze the effects of CAR-T cells on 3D tumor spheroid models using plate-based image cytometry. With this study, the authors demonstrate the potential benefits of using the proposed method for assessing multiple parameters such as potency, specificity and even location of the CAR-T cells in relation to the spheroids, which could improve the rate of identification for effective CAR-T cell therapies in the treatment of solid tumors.
Read this original research article to learn how image-based cytometry can overcome the limitations of conventional CAR-T characterization methods, along with more research articles in the April issue of SLAS Discovery.
The of SLAS Discovery includes these additional articles:
Access to the April issue of SLAS Discovery is available at
SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that:
- Enables and improves target validation
- Evaluates current drug discovery technologies
- Provides novel research tools
- Incorporates research approaches that enhance depth of knowledge and drug discovery success
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2021 Impact Factor 3.341. Editor-in-Chief Robert M. Campbell, Ph.D., Redona Therapeutics, Watertown, MA (USA)
###
RSS